Camp4 CSO receives 170,000 stock options grant

Camp4 Therapeutics Corp Chief Scientific Officer Daniel Tardiff received a grant of stock options covering 170,000 shares of common stock.

Rhea-AI Filing Summary

Camp4 Therapeutics Corp Chief Scientific Officer Daniel Tardiff received a grant of stock options covering 170,000 shares of common stock. The options have an exercise price of $4.46 per share and expire on March 31, 2036.

The options vest in equal monthly installments over four years starting from the grant date, aligning compensation with long-term company performance. Following this award, Tardiff holds 170,000 stock options directly, reflecting a routine, compensation-related equity grant rather than an open-market trade.

Insider Trade Summary

Grant/Award: 170,000 shares

Grant/Award 1 txn

Insider Tardiff Daniel

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	170,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 170,000 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying the option vest in equal monthly installments over a period of four years commencing from the date of grant.

Key Figures

Options granted: 170,000 options Exercise price: $4.46 per share Underlying shares: 170,000 shares +3 more

6 metrics

Options granted 170,000 options Stock Option (Right to Buy) grant to CSO

Exercise price $4.46 per share Conversion or exercise price of options

Underlying shares 170,000 shares Common stock underlying the options

Expiration date March 31, 2036 Option expiration date

Post-transaction options 170,000 options Total options held following transaction

Vesting schedule 4 years, monthly Equal monthly vesting from grant date

Key Terms

Stock Option (Right to Buy), exercise price, vest in equal monthly installments, Form 4

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 4.4600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in equal monthly installments financial

"shares underlying the option vest in equal monthly installments"

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CAMP report for Daniel Tardiff on this Form 4?

Camp4 Therapeutics reported that Chief Scientific Officer Daniel Tardiff received a grant of stock options for 170,000 shares. These options are a compensation award, not an open‑market purchase or sale, and give him the right to buy CAMP common stock at a fixed exercise price.

How many CAMP stock options were granted to the Chief Scientific Officer?

Daniel Tardiff was granted stock options covering 170,000 shares of Camp4 Therapeutics common stock. This award represents his total option holdings reported after the transaction, indicating a new equity incentive position tied directly to the company’s future share performance over time.

What is the exercise price and expiration date of the CAMP options?

The stock options granted to Daniel Tardiff have an exercise price of $4.46 per share and expire on March 31, 2036. This means he can choose to buy CAMP shares at $4.46 any time before the 2036 expiration date, subject to vesting conditions being satisfied.

How do the CAMP options granted to Daniel Tardiff vest over time?

The options vest in equal monthly installments over four years starting from the grant date. This structure gradually delivers exercisable rights each month, encouraging long‑term alignment with Camp4 Therapeutics’ performance rather than providing immediate full ownership rights on the grant date.

Is this CAMP Form 4 transaction a stock purchase or sale on the market?

No, this Form 4 reports a grant of stock options as compensation, not an open‑market trade. Daniel Tardiff did not buy or sell shares in the market; he received the right to purchase CAMP shares later at a fixed exercise price if he chooses.

What does total shares following the transaction mean for this CAMP option grant?

Total shares following the transaction of 170,000 reflects the number of underlying shares tied to Daniel Tardiff’s options after the grant. It indicates his reported option-based exposure to CAMP common stock from this award, assuming all granted options eventually vest and become exercisable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/03/2026 - 04:48 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tardiff Daniel

(Last) (First) (Middle)

C/O CAMP4 THERAPEUTICS CORPORATION

ONE KENDALL SQ., BLDG 1400 WEST, 3RD FL.

(Street)

CAMBRIDGE MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Camp4 Therapeutics Corp [ CAMP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.46	04/01/2026		A		170,000		(1)	03/31/2036	Common Stock	170,000	$0	170,000	D

Explanation of Responses:

1. The shares underlying the option vest in equal monthly installments over a period of four years commencing from the date of grant.

Remarks:

	/s/ Josh Mandel-Brehm, as Attorney-in-Fact	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)